Spinocerebellar ataxia (SCA) is a debilitating group of neurodegenerative disorders that progressively affect movement and coordination. Historically, treatment options have been limited to managing symptoms and improving quality of life. However, recent developments in research are offering new hope for patients with SCA. One promising avenue is

Multiple System Atrophy (MSA) affects a complex challenge for individuals and their loved ones. While there is currently no cure for MSA, a variety of treatment options and management strategies can help to reduce symptoms and improve quality of life. Pharmacological interventions often focus on addressing the specific manifestations of MSA, such